Company news
Nutriband Inc. (NASDAQ:NTRB) news
Nutriband Inc. news releases on 6ix. Latest, Sep 20, 2024: Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl…
Press releases — page 2
Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal Patch
September 19, 2024
Nutriband Inc. Authorizes $1M Share Buyback Program
September 15, 2024
Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology
July 14, 2024
Nutriband Provides Product Development Update for Its Lead Product Aversa Fentanyl
June 19, 2024
Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors
May 15, 2024
Nutriband Closes $8.4M Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission
April 23, 2024
Nutriband Inc. Signs Exclusive Supplier Agreement with Major Sports Brand Licensee Fit for Life Group
April 22, 2024
Nutriband Inc. Announces $8.4M Private Placement
April 18, 2024
Nutriband Inc. Begins Manufacturing for Major Sports Brand Licensee Fit for Life Group, Whose Collection of Partnered Brands Include Reebok, Adidas and New Balance
March 31, 2024
Nutriband Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal Patch
March 26, 2024
Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual Meeting
March 24, 2024
Nutriband Signs Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery for Aversa(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch
January 4, 2024
Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling
November 27, 2023
Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology Tape
November 7, 2023
Nutriband Unveils Groundbreaking Innovation in Transdermal Medications
September 19, 2023
Nutriband's Innovative Patent Breaks New Ground in Transdermal Medications
September 19, 2023
Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology
September 19, 2023
Nutriband Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
September 10, 2023
Nutriband Inc. Announces Donovan McNabb as AI Tape Brand Ambassador
August 29, 2023
Nutriband Inc. Launches AI Tape Brand Direct-to Consumer Offerings
July 26, 2023
Nutriband Increases Existing Credit Line to $5 Million USD for the Development of its AVERSA(TM) Platform Towards FDA Submission
July 13, 2023
Nutriband Receives Notice of Allowance for U.S. Patent Covering Transdermal Abuse Deterrent Technology
June 22, 2023
Nutriband Inc. Reports Revenue Up 46% in Fiscal 2023
April 26, 2023
Nutriband With Kindeva Drug Delivery Select Aversa(TM) Fentanyl Abuse Deterrent Formulation for Commercial Scale Manufacturing Process Development
April 3, 2023
Nutriband Secures $2 Million Line of Credit Financing Facility to be Used for Commercialization of AVERSA(TM) Abuse-Deterrent Transdermal Technology
March 27, 2023
Nutriband Inc. Commences Trading on Upstream Under NTRB
January 4, 2023
Nutriband Inc. to Officially Launch AI Tape brand in Q1 2023
December 28, 2022
Nutriband Approved for Dual Listing on Upstream
December 13, 2022
Nutriband Inc. Reports Record Revenue Up 118% YoY in Q3
December 4, 2022
Nutriband Receives Notice of Issuance from the Canadian Intellectual Property Office for its AVERSA(TM) Abuse Deterrent Transdermal Technology Patent
November 30, 2022
Nutriband Supports Newly Published CDC Opioid Prescribing Guidelines
November 7, 2022
Nutriband Inc. to Manufacture Fleur Marché-branded Wellness Patches Under Exclusive Agreement
October 26, 2022
Nutriband With Kindeva Drug Delivery Demonstrate Enhanced Abuse-Deterrent Characteristics for AVERSA(TM) Fentanyl
October 3, 2022
Nutriband Inc. Announces Application for Dual Listing on Upstream
October 2, 2022
Nutriband Inc. Provides Update on Seven-for-Six Forward Stock Split
August 15, 2022
Nutriband Inc. Details of Seven-for-Six Forward Stock Split
August 9, 2022
Nutriband Receives Notice of Allowance from the Canadian Intellectual Property Office for its AVERSA(TM) Abuse Deterrent Transdermal Technology Patent
July 31, 2022
Nutriband Inc. Announces Seven-for-Six Forward Stock Split
July 26, 2022
Nutriband Inc. Registers New Company Branch in Ecuador with Plans to Expand into the South American Market
July 21, 2022
Nutriband Inc. Successfully Obtains Court Verdict for Recovery of Shares Constituting 15% of Its Total Outstanding Shares
July 14, 2022
Nutriband Inc. to Present at the Emerging Growth Conference on May 25
May 19, 2022
Nutriband Inc. Receives Orders for $230,000 in Contract Manufacturing for First 3 Weeks of May
May 16, 2022
Nutriband Subsidiary Active Intelligence LLC Registers with FDA as a Medical Device Manufacturer for its AI Kinesiology Tape Product
May 10, 2022
Nutriband Inc. Reports Revenue Up 56% in Fiscal 2022 to a Record $1.4M
April 28, 2022
Nutriband Issued Full US Patent for Its Aversa(TM) Abuse Deterrent Transdermal Platform by United States Patent and Trademark Office
January 27, 2022
Nutriband Inc. Expands Product Development Pipeline for Its AVERSA(TM) Platform Abuse Deterrent Technology
January 17, 2022
Nutriband Inc. And Kindeva Drug Delivery Sign Feasibility Agreement to Develop AVERSA(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch
January 9, 2022
Nutriband Inc. Announces $1 Million Share Repurchase Authorization
December 28, 2021
Nutriband Inc. Initiates Plans to Offer Topical Lotion Contract Manufacturing Services
December 20, 2021
Nutriband Inc. Receives cGMP Certification for Manufacturing Subsidiary
December 12, 2021